Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03612856Phase 2Completed

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

Role: lead

NCT03963895Phase 2Completed

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Role: lead

NCT03453060Phase 1Completed

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

Role: lead

NCT03097341Phase 1Completed

Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects

Role: lead

All 4 trials loaded